Ascendia

  MARKET NEWS

Andelyn Biosciences & Purespring Therapeutics Partner to Manufacture Novel Gene Therapies for Kidney Diseases
Evonik Launches EUDRACAP Preclinic Functional Oral Capsule for Preclinical Trials
IMUNON Announces First Patient Enrolled in Phase 1/2 Clinical Trial of IMNN-001 in Combination With Bevacizumab in Advanced Ovarian Cancer
Lisata Therapeutics Announces EMA Has Granted LSTA1 Orphan Drug Designation for the Treatment of Pancreatic Cancer 
Lumen Bioscience Awarded $16.2 Million in DoD Funding to Advance LMN-201 Through Late-Stage Trials
ABVC BioPharma Announces Completion of Subject Recruitment for Interim Analysis on ADHD Phase 2b Clinical Study

  FEATURED EDITORIAL

  COMPANY PROFILE

Labcorp provides industry leading preclinical medical device and combination product testing, as well as consulting and risk assessment solutions to help support you and your device from the earliest stages of study design to GLP assessments. With over 40 years of experience, our 150+ dedicated and highly experienced specialists have deep knowledge of delivering comprehensive preclinical testing, along with regulatory and compliance guidance that will provide you the answers, clarity, and confidence required to accelerate the development of your device or product. Gain efficiencies by leveraging our end-to-end testing portfolio that includes biocompatibility, microbiology/reusability validation, analytical chemistry, efficacy, and surgical services. Let’s work together to give your device a healthy start. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Aldena Therapeutics Selects PCI Pharma Services to Manufacture & Distribute Innovative Investigational Treatment for Dermatological Diseases

Aldena Therapeutics Selects PCI Pharma Services to Manufacture & Distribute Innovative Investigational Treatment for Dermatological Diseases

Aldena Therapeutics has chosen PCI Pharma Services (PCI) to formulate, package, and distribute ALD-102, an siRNA-based investigational injectable treatment for….

Ovid Therapeutics & Ligand Pharmaceuticals Enter -Million Agreement

Ovid Therapeutics & Ligand Pharmaceuticals Enter $30-Million Agreement

Ovid Therapeutics Inc. and Ligand Pharmaceuticals Incorporated recently announced Ligand has acquired a 13% portion of the royalties and milestones owed to Ovid related to the potential approval and commercialization of….

Datwyler Introduces Ready-for-Sterilization Combiseals to Enhance Efficiency in Drug Filling & Packaging

Datwyler Introduces Ready-for-Sterilization Combiseals to Enhance Efficiency in Drug Filling & Packaging

Ready-for-sterilization (RFS) combiseals for cartridges take the burden off drug manufacturers to prep packaging components for sterilization, saving time and cost while complying with FDA and EU regulations…..

Vetter Announces 230+ Million Euro Investment to Meet Supply Chain Demand

Vetter Announces 230+ Million Euro Investment to Meet Supply Chain Demand

Vetter recently announced additional investments as part of its long-term dedication to customer partnerships. Vetter’s extensive 40+ years of experience in aseptic filling and packaging shows a consistent desire for sustainable growth and corporate development…..

Monte Rosa Therapeutics Announces Strategic Collaboration With Roche

Monte Rosa Therapeutics Announces Strategic Collaboration With Roche

Collaboration combines Monte Rosa Therapeutics’ highly differentiated QuEEN discovery engine with Roche’s strong expertise in delivering transformative therapies to patients….

  WHITEPAPERS & WEBINARS

WEBINAR - Nanoparticle Suspensions: History, Applications & CMC Aspects

WEBINAR - Nanoparticle Suspensions: History, Applications & CMC Aspects

This webinar describes the history, CMC aspects, and potential applications of nanoparticle suspensions (NSs). This drug delivery technology should be considered for crystalline, sparingly water-soluble APIs. The presentation highlights….

WEBINAR - Impact of Process Re-design on Sustainability in Pharmaceutical Small Molecule Manufacturing

WEBINAR - Impact of Process Re-design on Sustainability in Pharmaceutical Small Molecule Manufacturing

Join us for an upcoming webinar that delves into a crucial issue in the pharmaceutical industry. Recent research has revealed a surprising fact: the pharmaceutical sector has a larger carbon footprint than even the automotive industry, especially when we consider the entire supply chain’s impact on

WEBINAR - Beyond the Lab: Unleashing the Potential of In Silico Modeling in Drug Product Formulation

WEBINAR - Beyond the Lab: Unleashing the Potential of In Silico Modeling in Drug Product Formulation

In this webinar you will learn how digital chemistry tools facilitate rapid screening of formulation parameters, aiding in the identification of optimal drug delivery systems, excipient selection, and dosage forms….

  WHITEPAPERS & WEBINARS

WHITEPAPER - Accelerate Preclinical Developments & Improve Oral Bioavailability With Lipid-Based Formulation & Encapsulation Technology Combination

WHITEPAPER - Accelerate Preclinical Developments & Improve Oral Bioavailability With Lipid-Based Formulation & Encapsulation Technology Combination

Owing its convenience, oral administration is patients’ preferred route of delivery for therapeutic molecules. However, most New Chemical Entities (NCE) exhibit physico-chemical properties limiting their absorption in the gastro-intestinal (GI) tract. Indeed, according to Pharmacircle data from March 2022, almost …

WHITEPAPER - Monitoring Low Dose API Blend Uniformity With Parteck® M Mannitol Using Near-Infrared (NIR) Spectroscopy

WHITEPAPER - Monitoring Low Dose API Blend Uniformity With Parteck® M Mannitol Using Near-Infrared (NIR) Spectroscopy

Direct compression is often used for tablet manufacturing because it is the shortest, most effective, and least complex method. The physical properties of active pharmaceutical ingredients (APIs) can, however, create a challenge for flowability and compressibility, and, as a result, …

WHITEPAPER - Streamline Early-Stage Development to Reach the Clinic Faster

WHITEPAPER - Streamline Early-Stage Development to Reach the Clinic Faster

Early-stage development is critical to shortening your product’s timelines while establishing a solid foundation for clinical trials. In this insightful article from Dr. Srinivasan Shanmugam, Adare’s Executive Director of Pharmaceutical Sciences, learn what’s needed to make your product’s early-stage development …

WHITEPAPER - The Viscosity Reduction Platform: Viscosity-Reducing Excipients for Protein Formulation

WHITEPAPER - The Viscosity Reduction Platform: Viscosity-Reducing Excipients for Protein Formulation

Protein viscosity is one of the major obstacles in preparing highly concentrated protein formulations suitable for subcutaneous (subQ) injection. SubQ application of highly concentrated protein formulations enables a higher patient convenience and might thus lead to reduction in health costs. …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

November 1 – Formulation Development
November 8 – Drug Delivery